GET DAILY SIGNALSCOMPASS Pathways (CMPS) Narrows Q3 Loss as NDA Filing Nears Completion
Key Takeaways
- COMPASS Pathways reported a third-quarter 2026 net loss of $9.83 million, sharply narrower than the $137.72 million loss in the same period a year earlier.
- Diluted loss per share was $0.31, versus $1.44 a year ago; the GAAP loss of $0.31 per share beat analyst consensus by $0.10.
- The company remained pre-revenue, posting $0.0 million in sales as expected, while operating loss widened as launch preparation costs climbed.
- Cash and cash equivalents reached $443.98 million at September 30, 2026, up from $149.6 million at the end of 2025, funding operations into 2028.
- Management said the rolling New Drug Application (NDA) for COMP360 in treatment-resistant depression will be completed within two weeks, with a targeted commercial launch in the first half of 2027.
Earnings Context and Why It Matters
COMPASS Pathways is a clinical-stage biotechnology company developing COMP360, an investigational synthetic psilocybin therapy for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Because the company has not yet launched a commercial product, its quarterly results carry no revenue and are measured instead by cash burn, clinical progress, and regulatory milestones. The third quarter of 2026 matters most because COMP360's rolling New Drug Application is nearing completion, positioning COMPASS as a potential first mover in a new category of mental health treatments. With a National Priority Voucher potentially enabling an accelerated review, investors are watching this report less for the loss figure itself and more for signals on approval timing, launch readiness, and the strength of the balance sheet. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the three months ended September 30, 2026, COMPASS Pathways reported a net loss of $9.83 million, compared with $137.72 million in the prior-year quarter. The narrower loss was driven largely by a $40.78 million non-cash fair-value gain on warrant liabilities, versus a $101.32 million loss in the same period a year ago. On a diluted basis, the company posted a loss of $0.31 per share, improved from $1.44 per share a year earlier and ahead of consensus expectations.
Revenue remained at zero, consistent with a pre-commercial company. Operating loss widened to $56.44 million from $40.54 million, as selling, general and administrative (SG&A) expenses climbed to $32.98 million from $13.21 million a year ago, reflecting investment in commercial infrastructure ahead of a potential 2027 launch. Research and development (R&D) spending declined to $23.46 million from $27.33 million as Phase 3 TRD trial costs rolled off.
For the nine months ended September 30, 2026, net loss was $172.42 million, compared with $193.98 million a year earlier, and diluted loss per share was $1.35 versus $2.09.
Market Reaction and Investor Sentiment
Shares of COMPASS Pathways moved higher following the November 3, 2026 report, reflecting relief that the bottom-line beat coincided with a clearer timeline for the COMP360 filing. Because the company is pre-revenue, the market's response was driven less by the loss-per-share figure than by the regulatory narrative. Management confirmed that the rolling NDA would be completed within two weeks and reiterated confidence that the National Priority Voucher could support a one-to-two-month review target at the U.S. Food and Drug Administration (FDA).
Sentiment remains shaped by both opportunity and risk. On the positive side, the company highlighted a stronger cash position and commercial preparation. On the cautionary side, investors continue to weigh uncertainty around Drug Enforcement Administration (DEA) rescheduling, state-level rescheduling timelines, reimbursement code transitions, and speculation about potential competing psilocybin programs.
Forward Outlook and Key Factors to Monitor
The next several quarters will be defined by execution rather than financial results. The immediate milestone is completion of the NDA submission, expected within two weeks of the report. From there, attention turns to the FDA's acceptance and review timeline, with the National Priority Voucher potentially compressing the process to a one-to-two-month review window.
Investors should monitor the rescheduling pathway closely. Federal DEA rescheduling must be followed by state-level actions, and management has indicated that states representing more than 93% of the U.S. population have signaled intent to reschedule within 30 days of federal action. Reimbursement is another key factor, as the company expects a transition from Category III to Category I billing codes over roughly 12 to 18 months, with patient support programs bridging the early launch period.
Commercial readiness will also be a focus. COMPASS has filled its planned non-field commercial roles and is now building a field force, while the network of interventional psychiatry treatment centers has grown beyond 8,500 sites. Management plans to report launch metrics such as Risk Evaluation and Mitigation Strategy (REMS) certifications, prescriptions, prescribers, and payer access through 2027. With roughly $444 million in cash, the company has stated its balance sheet is sufficient to carry it through launch and into 2028, though rising commercial spending is expected to persist as the organization scales toward a targeted first-half 2027 launch.
Using AI Tools for Biotech Research
In my analysis of clinical-stage biotech names, Tickeron’s AI Screener has become a regular part of the process. It allows quick filtering by industry, fundamentals, and technical signals, which helps surface comparable opportunities without manual effort. The tool has been particularly useful when evaluating pre-revenue companies like this one against broader sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CMPS in downward trend: 10-day moving average crossed below 50-day moving average on October 02, 2026
The 10-day moving average for CMPS crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 54 cases where CMPS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMPS as a result. In 72 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for CMPS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for CMPS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CMPS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +11.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMPS advanced for three days, in 226 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CMPS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CMPS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.072) is normal, around the industry mean (204.027). P/E Ratio (-2.266) is within average values for comparable stocks, (19.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.092) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement